The structural basis for the phospholipid remodeling by lysophosphatidylcholine acyltransferase 3

Qing Zhang, Deqiang Yao, Bing Rao, Liyan Jian, Yang Chen, Kexin Hu, Ying Xia, Shaobai Li, Yafeng Shen, An Qin, Jie Zhao, Lu Zhou, Ming Lei, Xian-Cheng Jiang & Yu Cao

As the major component of cell membranes, phosphatidylcholine (PC) is synthesized de novo in the Kennedy pathway and then undergoes extensive deacylation-reacylation remodeling via Lands’ cycle. The re-acylation is catalyzed by lysophosphatidylcholine acyltransferase (LPCAT) and among the four LPCAT members in human, the LPCAT3 preferentially introduces polyunsaturated acyl onto the sn-2 position of lysophosphatidylcholine, thereby modulating the membrane fluidity and membrane protein functions therein. Combining the x-ray crystallography and the cryo-electron microscopy, we determined the structures of LPCAT3 in apo-, acyl donor-bound, and acyl receptor-bound states. A reaction chamber was revealed in the LPCAT3 structure where the lysophosphatidylcholine and arachidonoyl-CoA were positioned in two tunnels connected near to the catalytic center. A side pocket was found expanding the tunnel for the arachidonoyl CoA and holding the main body of arachidonoyl. The structural and functional analysis provides the basis for the re-acylation of lysophosphatidylcholine and the substrate preference during the reactions.

1CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 333 Haike Road, Shanghai 201210, China. 2Institute of Precision Medicine, the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 115 Jinzun Road, Shanghai 200125, China. 3State Key Laboratory of Oncogenes and Related Genes, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. 4Department of Orthopaedics, Shanghai Key Laboratory of Orthopaedic Implant, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. 5Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201203, China. 6Department of Cell Biology, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA. 7These authors contributed equally: Qing Zhang, Deqiang Yao, Bing Rao. ✉Email: yu.cao@shsmu.edu.cn

https://doi.org/10.1038/s41467-021-27244-1
Phospholipids (PLs) make up the major lipids in cellular membranes and in the circulation. PLs are synthesized de novo by the Kennedy pathway. The asymmetrical distribution of fatty acids at the sn-1 and sn-2 positions is maintained in part by a deacylation-reacylation process first proposed by Lands 60 years ago (Lands' Cycle or PL remodeling). The reacylation is catalyzed by lysophospholipid acyltransferase. So far, no structure has been resolved in this set of enzymes. Phosphatidylcholine (PC) is a major PL and its composition in mammalian cell membrane exhibits considerable structural diversity. Four lysophosphatidylcholine acyltransferases (LPCATs), LPCAT1–4, participate PC remodeling by Lands et al. Among them, LPCAT3 is the main isoform in major metabolic tissues, including the liver, small intestine, skeletal muscle, macrophage, and adipocyte. LPCAT3 is regulated by liver X receptor, a well-known factor in control of lipogenesis. LPCAT3 activity influences the biology and pathology of these tissues and plays an important role in lipoprotein production in the liver and small intestine. Intestinal LPCAT3 activity is required for a gut-brain feedback loop that couples absorption to food intake. LPCAT3 deficiency reduces lipid absorption, thus reducing atherosclerogenic lipoproteins in the circulation. LPCAT3 deficiency increases insulin sensitivity in skeletal muscle, through modulating plasma membrane PC composition, and impairs preadipocyte adipogenesis through activating Wnt/beta-catenin pathway. In terms of atherogenicity, the reported studies are controversial. On the one hand, the expression of LPCAT3 is associated with atherosclerosis progression. On the other hand, although LPCAT3 deficiency in macrophage increases the production of inflammatory and atherogenic cytokines/chemokines, however, this effect may or may not promote the development of atherosclerosis. Collectively, LPCAT3 is a potential target for the treatment of metabolic disorders such as hyperlipidemia and atherosclerosis. However, some concerns are noted, for instance, the disruption of LPCAT3 could promote the tumorigenesis in the intestine, probably by increasing the cholesterol biosynthesis in the intestinal stem cells and thus enhancing its proliferation; blocking LPCAT3 might cause fat accumulation in tissues.

LPCAT1 and 2 are type II single-pass membrane proteins containing LPA acyltransferase motifs, and LPCAT3 and 4 are multi-pass membrane proteins. LPCAT3 belongs to the membrane-bound O-acyltransferase (MBOAT) family, which includes over 10,000 multi-pass membrane proteins found in species ranging from bacteria to mammals (details available at http://pfam.xfam.org/family/MBOAT). LPCAT3, aka MBOAT5, is one of the eleven MBOATs found in the human genome and share about 10–20% protein identity with its human relatives. SOAT1 and DGAT1 are two human MBOATs with structures recently solved, but the evolutionary diversity made it difficult to understand the lysOPls acyltransferases mechanism using currently available structures as models. To probe the molecular mechanism underlying acyl transfer process in phospholipids remodeling and the unsaturation preference on the acyl to be transferred, we determined the crystal and cryo-EM structure for chicken LPCAT3 and explored the function of the critical residues implied by the structures.

**Results**

The crystal structure of chicken LPCAT3. The human and chicken LPCAT3 share a protein sequence identity of about 69% (Supplementary Fig. 1). Both chicken LPCAT3 (cLPCAT3) and human LPCAT3 (hLPCAT3) purified in various detergents display significant acyltransferase activities in thin layer chromatography (TLC) assay using arachidonoyl CoA (araCoA) and NBD-labeled 12:0 LPC as substrates where the formation of NBD-PC by acyl transfer were monitored through the relative mobility shift of the sample bands with the fluorescence from NBD group. Compared with hLPCAT3, cLPCAT3 showed better homogeneity in the gel filtration and higher acyltransferase activity in TLC assay, implying superior stability for cLPCAT3. To probe the catalytic mechanism, extensive efforts in protein engineering and crystallization were conducted on hLPCAT3 and cLPCAT3, but most of them failed. When purified in undecyl maltoside (UM) and treated with trypsin digestion, cLPCAT3 was trimmed into a slightly smaller protein core with only two residues at C-terminal removed along with the affinity tag (hereafter cLPCAT3core) and yielded crystals with diffraction to about 3.4 Å resolution, allowing the structure determination of cLPCAT3 by molecular replacement using a molecular model predicted by Tencent tFold server.

Overall, cLPCAT3core crystallized in the monomeric form, and residues 42–459 were resolved in each protomer (Fig. 1b and Supplementary Fig. 3a). The monomeric cLPCAT3core adapts into a bell-shaped overall structure with 11 transmembrane helices (TM1–11) and 6 shorter helices at the membrane-embed region (Ha-f) (Fig. 1b, c). No signaling peptide sequence was identified at the N-terminus of both cLPCAT3 and hLPCAT3 and both N-terminus were predicted to localized in the cytoplasmic side of the ER membrane by Phobius (https://phobius.sbc.su.se/). The transmembrane helices of cLPCAT3 gather into two wing-shape domains, an N-terminal wing (N-wing) comprising helices TM1–6, and a C-terminal wing (C-wing) comprising helices TM8–11, with the longest helix, TM7, extending from C-wing to N-wing (Fig. 1c). The helices in N- and C-wings tilt to converge at the cytoplasmic side and thus form a large cavity embedded in the exoplasmic leaftet of the ER membrane and open to the ER lumen, which is filled with loops and Ha-f (Fig. 1c, d). This wing-cavity architecture resembles the folding in previously reported MOBATs, i.e. SOAT1 and DGAT1 (Supplementary Fig. 4c), where the cavity between the wings serves as a reaction chamber for the O-acyltransferase activity. Despite their diversities in protein sequences (cLPCAT3 vs DGAT1: 13.57%; cLPCAT3 vs SOAT1: 12.86%), the proteins in structural superposition align well in their spatial arrangement, saving the exception that the membrane topology of LPCAT3 is opposite against SOAT1 and DGAT1.

The structural analysis using the program HOLLOW shows a “T”-shape inner chamber enclosed by TM helices and Hd-f (Fig. 1d, e). In general, this T-shape chamber is composed of a “horizontal” tunnel parallel to the ER membrane and proximal to the cytoplasmic side, which connects with a “vertical” tunnel at the middle point (Fig. 1e). The horizontal tunnel extends from the N-wing to the C-wing and its tip in the N-wing ends at a gap between TM1 and 6 (Fig. 1d), which opens laterally to the lipid environment of the ER membrane and thus might represent a potential gate for the chamber (hereafter lateral gate). The vertical tunnel is perpendicular to the horizontal tunnel and extends to the ER lumen, with a small “side pocket” extruding in the middle (Fig. 1e). The T-shape chamber is empty in the crystal structure and the analysis on the Fo-Fc electron map failed to identify any non-proteinous density. To explore the mechanism for acyltransferase activity, further efforts in electron microscopy were conducted to determine the LPCAT3 structure in the substrate-bound states.

The cryo-electron microscopy analysis of cLPCAT3. Only crystals of substrate-free cLPCAT3 can diffract to a resolution beyond 4 Å and co-crystallization of cLPCAT3 with either LPCs

---

**ARTICLE**

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27244-1 | www.nature.com/naturecommunications
or acyl-CoAs failed to generate crystals capable of diffracting to 5 Å. To further explore the substrates binding and catalytic mechanism of LPCAT3, we turned to electron microscopy (EM) to determine the alternative conformations for LPCAT3. Initial efforts on single-particle analysis on cLPCAT3 samples prepared for crystallization failed to conduct a reliable 2-D classification due to the small size of monomeric LPCAT3. Extensive detergent screen in membrane solubilization and gel-filtration separation showed that a proper proportion of cLPCAT3 protein could form an oligomer when extracted from the membrane using Lauryl Maltose Neopentyl Glycol LMNG, instead of DDM (Supplementary Fig. 2). After solubilization with LMNG, the oligomeric LPCAT3 was further separated from its monomers by size-exclusion chromatography in glyco-diosgenin (GDN) supplemented with 0.2 mM arachidonoyl CoA. Cryo-EM images of cLPCAT3 were collected using a Titan Krios transmission electron microscope.

**Fig. 1 The crystal structure of monomeric cLPCAT3.** a The purification and functional assay of human and chicken LPCAT3. Blue and red curves show the size-exclusion chromatography profiles of the chicken and human LPCAT3 protein, respectively. The left inset shows the SDS-PAGE analysis on the fractions collected from the size-exclusion chromatography. The right inset shows the TLC assay on the enzymatic activities of the fractions. The experiment has been repeated three times with success. b Cartoon representation of cLPCAT3 monomer topology. The TM helices 1-11, N-terminal helix NH, membrane-embedded helices a-f, the cytoplasmic helix CH, and the lumenal helix LH were colored according to the same scheme as in (c). The cell membrane was shown as steel gray block and the orientation labeled according to the calculation using PPM server (https://opm.phar.umich.edu/ppm_server). c Left: the cLPCAT3 molecular model viewed parallel to the ER membrane; Right: the cLPCAT3 molecular model viewed from the lumen side of the ER membrane. d The T-shape chamber of cLPCAT3. The internal cavity within cLPCAT3 as determined by program HOLLOW was shown as surface in golden and the cLPCAT3 was shown as the cartoon model, with the lateral gate-forming helices TM1 and TM6 in red and blue, respectively. e A close view of the T-shape chamber. All structure graphs in this and the following figures were generated with PyMOL (The PyMOL Molecular Graphics System, Version 1.9 Schrödinger, LLC.) and UCSF ChimeraX (The UCSF Resource for Biocomputing, Visualization, and Informatics, version 1.2).
electron microscope (FEI) operated at 300 kV, and data processing was performed using RELION3 and cryoSPARC41,42. Both 2D- and 3D-classification on the particles indicated that cLPCAT3 forms homodimer in samples (Supplementary Fig. 5). The 3D refinement using C2 symmetry generated an EM density map with an overall resolution of 3.49 Å and a resolution of about 3 Å at the core region of cLPCAT3 protomers (Fig. 2a and Supplementary Fig. 5). Similar data collections and refinement processes were conducted on the cLPCAT3 samples supplemented with 0.5 mM 1-dodecanoyl-sn-glycero-3-phosphocholine (12:0-LPC) and EM maps were generated at an overall resolution of 3.57 Å (Fig. 3a and Supplementary Fig. 6). The molecular models for the dimeric cLPCAT3/araCoA and cLPCAT3/LPC were thus built in the corresponding EM maps (Figs. 2b, 3b and Supplementary Fig. 7), respectively, using the crystal structure of cLPCAT3core as the starting model, which showed that the cLPCAT protomers in both the araCoA- and LPC-bound state adapt into a structure similar to the monomeric crystal structure of cLPCAT3core (RMSDs among the main chains: 0.819–0.823 Å) (Supplementary Fig. 4a, b).

The catalytic chamber and substrates bound. A large non-protein electron density was observed in the EM map calculated with the LPCAT3 pre-incubated with 0.2 mM araCoA, which stretches along the vertical tunnel and is surrounded by helices TM8, 9, 10, and membrane-embedded helices He and Hf (Fig. 2b, c). An arachidonoyl CoA molecule was fit very well in the

![Fig. 2 The cryo-EM structure of cLPCAT3 bound with araCoA. a]## (https://doi.org/10.1038/s41467-021-27244-1) cLPCAT3 cryo-EM map viewed from the lumen side of the ER membrane. The two protomers in dimeric cLPCAT3 were shown in red and blue, respectively. The non-protein electron density at the dimeric interface was shown in gray. b The cartoon representation of cLPCAT3/araCoA molecular model. The non-protein electron density in the vertical tunnel and side pocket was shown in the pink surface and the araCoA molecules that fit in the density were shown as a stick-and-ball model. Upper: the cLPCAT3 viewed parallel to the ER membrane. Lower: the cLPCAT3 viewed from the lumen side of the ER membrane. One of the protomers was colored to the same scheme as in Fig. 1c for clear observation. c The binding of the araCoA within the vertical tunnel and side pocket. The intersecting surfaces of the T-shape chamber of cLPCAT3 were shown parallel to the ER membrane at two angles. The vertical tunnel and side pocket were highlighted in green and yellow color, respectively. d The interaction of araCoA with residues in the vertical tunnel and side pocket. The catalytic residue N352 was marked with an asterisk. e The TLC assay results on the purified wild type cLPCAT3 (dark column) and araCoA-related mutants (gray columns). The enzymatic activities of mutants were normalized as the percentage of that of wild type cLPCAT3. The results were shown as mean ± s.d.; n = 3 independent experiments for all mutants. One-way ANOVA with Dunnett’s multiple comparisons test was applied and the 95% CI was calculated by Graphpad Prism (version 6.01), and p-values were labeled above the histogram.
electron density, where the co-enzyme A moiety sits into the large blob of electron density at the ER luminal face, while the narrow, long density corresponding to the 20:4 acyl chain stretches deep into the chamber and form a U-turn with the polysaturated scaffold of arachidonoyl group to enter the side pocket (Fig. 2c), allowing the vertical tunnel accommodates the oversized arachidonoyl group and saving the space in the horizontal tunnel for the acyl acceptor LPC. The cytoplasmic end of the vertical tunnel is lined with positively charged amino acids and thereby provides a docking surface for the coenzyme A moiety, where the binding of CoA is stabilized by the electrostatic interactions among the pyrophosphate section of CoA and basic residues R409, as well as K365, 368, and 373 (Fig. 2d). The araCoA extends into the T-shape chamber and turns at the joint point near H388 to a “side pocket” with its double-bonds in the acyl chain (Fig. 2c), and the carbonyl oxygen of the arachidonoyl pointing to the conserved residue N352, implying its role as protonation reagent in the hydrolysis of thioester bond. When N352 was mutated, the cLPCAT3 show an impaired acyltransferase activity, confirming its critical role in the reaction (Fig. 2e). To hold the acyl chain, the side pocket is in general lined with hydrophobic residues, e.g., F344, I348, I404, M446, and L450, and the functional assay showed that the mutations on those sites could reduce the enzymatic activities to various degrees (Fig. 2e). Unexpectedly, the E401A mutation fully abolished the acyltransferase activity (Fig. 2e), implying the importance of E401 in maintaining the binding of the acyl-CoA molecule.

In the cryo-EM map for cLPCAT3/LPC, the non-protein electron density found in the horizontal tunnel with no overlap with the araCoA electron density found in the EM map for cLPCAT3/araCoA (Fig. 3a, b). The C12:0-LPC molecule fits well in the density with the phosphocholine head positioned in the C-wing side and stabilized by the interactions with a series of hydroxy groups from tyrosine Y143, Y151, Y298, and Y394 (Fig. 3c). When the interactions were impaired by the mutations of those tyrosine residues, the enzymatic activities of cLPCAT3 reduced significantly (Fig. 3d). The C12:0-acyl at sn-1 of the LPC extends to the N-wing side of the horizontal tunnel and ends near to the lateral gate formed by TM1 and 6 (Figs. 1d and 3b), where the binding of acyl chain is mediated by its hydrophobic interaction with residues L58, I59, Y151, I153, L155, and V213. The sn-2 hydroxy of the glycerol backbone is close to the catalytic residue H388 (Fig. 3c), ready to be activated into a nucleophilic reagent through the deprotonation by the imidazolyl of the histidine.

The structural implication of the acyltransferring mechanism. Previous structural studies on lipid acyltransferases, e.g. DGAT1 and SOAT1, revealed the entrance and binding of acyl donor molecules in enzyme, and the catalytic mechanism were proposed combined the experimental molecular model and putative binding pocket for acyl receptor. Previous structural studies on lipid acyltransferases, e.g. DGAT1 and SOAT1, revealed the entrance and binding of acyl donor molecules in enzyme, and the catalytic mechanism were proposed combined the experimental molecular model and putative binding pocket for acyl receptor. In our studies on LPCAT3, the acyl donor and receptor molecules bound are visible in two EM maps with an adjacent but separate spatial arrangement, allowing a straightforward analysis of the acyl transferring process. Since the protein backbone in the structures of LPCAT3 bound with LPC and araCoA are in general consistent, the two EM models for LPCAT3 were merged to generate a working model for LPCAT3 (Fig. 4a, b). The T-shape chamber with the side pocket could allow the enzyme to capture the acyl donor and receptor simultaneously, where the carbonyl oxygen of the acyl donor and the sn-2 hydroxy of the acyl receptor could be activated by N352 and H388, respectively (Fig. 4c). The reaction could be then continued by the formation of the ester bond between the oxygen
of sn-2 hydroxy and carbon of protonated carbonyl, followed by the breakage of the thioester bond to release the PC product from the intermediate. In the end, the CoA molecule thereby formed exits from the vertical tunnel into the ER lumen, while the PC molecule might enter the ER membrane through the lateral gate (Fig. 5a, b). The enzymatic activity of LPCAT3 was improved by the mutations on the residues at the lateral gate, e. g., I59A (Figs. 3d and 5b), implying the gating function of I59 for limiting the passage of PC/LPC. An even higher rise in enzymatic activity was found on cLPCAT3 K297A, which could relieve the steric hindrance from the cation-aromatic interaction between Y151 and K297 (Fig. 5b).

When studying DGAT1 in the acyl donor-bound state, Sui et al. showed a lipid-like density co-localized in the reaction chamber which might represent the DAG molecule as the acyl receptor36. In our EM map for acyl donor-bound state of DGAT1, we observed a lipid-like density co-localized in the reaction chamber which might represent the DAG molecule as the acyl receptor. This observation suggests that the DAG molecule is bound to the enzyme in the acyl donor-bound state.
(cLPCAT3/araCoA), the binding cavity for LPC holds some small blobs of electron density and no continuous density was visible there (Supplementary Fig. 9b). Interestingly, despite the empty vertical tunnel in our EM map for acyl receptor-bound state (cLPCAT3/LPC), a long, lipid-like density was revealed in the side pocket which meets the electron density of LPC at the joint point near to H388 (Fig.4d). Manually modeling the acyl of LPC into the density failed to generate well-fit models, suggesting this lipid-like density might not represent an alternative conformation of LPC molecules bound (Supplementary Fig. 9a). Based on the absence of density corresponding to the CoA moiety, we speculated that this unmodeled density, in combination with the large density for LPC, might represent the PC product partially bound and co-puriﬁed with the protein. Further studies should be conducted to probe the identity of this density and the exit mechanism for remodeled PC.

The non-contact dimer of LPCAT3. Although the electron microscopy analysis showed that cLPCAT3 could be puriﬁed as a dimer with relatively mild detergent LMNG, cLPCAT3 shows an unusual dimerization conformation without any physical contact between two protomers. Only seven residues stay at a distance less than 5 Å from the neighboring protomer and the shortest distance between two protomers is about 4.4 Å (Fig. 6b), insufﬁcient for stable dimer maintenance. The mutations of residues at the close point of the dimer interface, such as T126K/L372K double mutation, cannot disrupt the dimer, implying the limited involvement of the residue sidechains in the dimerization of LPCAT3 (Fig. 6d). The cryo-EM map analysis on cLPCAT3/araCoA revealed the non-protein electron density sandwiched by cLPCAT3 protomers (Fig. 2a) and two 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) molecules were well modeled into the large blobs of electron density (Fig. 6c and Supplementary Fig. 7). This non-contact dimerization might be mediated by those intermediary lipid molecules and the relatively harsh detergents used in the crystallization trial deprived the cLPCAT3 of the lipids bound, resulting in the monomeric biological unit in cLPCAT3 crystals. To probe the natural oligomeric state of LPCAT3 in the membrane, cross-linking assays were conducted on membrane preparations from the Expi293 cells overexpressing the corresponding proteins. Shown were the representative results from three independent experiments.

Discussion

LPCAT3 plays a major role in modulating the level of polyunsaturated PLs in the cellular membrane system, especially that of arachidonoyl-containing PCs. The substrate preferences of LPCAT3 on the polyunsaturated acyl chain of the acyl donor and the phosphocholine group of the acyl receptor, however, are yet to be elucidated. In the T-shape catalytic chamber revealed in our LPCAT3 structure, the length of the vertical tunnel is limited...
and could only accommodate the CoA moiety with a short acyl group. The side pocket substructure extruding from the vertical tunnel expands the space for acyl-CoA, but its near-to-90° stretching routine from vertical tunnel might be unfavorable for capturing the chemical structure of saturated acyl chain, such as oleoyl. Although the C–C single bonds render the saturated carbon chain with more flexibility, the stable staggered rotamers of C–C single bond tend to keep the saturated acyl in an extended, all-trans configuration, making the large-angle bending of the carbon chain energetically unfavorable. All the cis-configuration in polyunsaturated acyl chain, such as a 20:4 acyl, could help carbon chain adapt into a ring-shape structure fitting the side pocket very well, while a saturated acyl chain with moderate length, such as 18:0 or 16:0, would suffer from stereo-hindrance for their straighter conformation and thus be catalyzed with significantly poorer efficiency. This substrate preference mechanism is supported by the substrate preference studies by Zhao et al., where the LPCAT3 showed the highest acyltransferase activities using long polyunsaturated acyl-CoA (20:4 and 18:2) as acyl donor, while a preference on shorter carbon chain was observed on the saturated acyl-CoA (12:0 > 16:0 > 18:0).12

In precedent biochemical assays on LPCAT3, it was shown that it catalyzes acyl transferring reaction with a hill coefficient of about 2 (from 1.4 to 3.7 for different acyl-CoAs), implying the existence of oligomeric LPCAT45. Although crystallized as a monomer, the cLPCAT3 forms dimer in both membrane-bound state and subsequent EM analysis in detergents. Different from dimeric DGAT1 or SOAT1,35,57 LPCAT3 dimerizes at helices TM3, 4, and 8, which align well with the distal region from the dimeric interface in DGAT1 and SOAT1 dimer (helices TM2, 3, and 7 of DGAT and SOAT1, respectively, see Supplementary Fig. 8b). This alternative architecture of LPCAT3 dimer exposes its lateral gate to the ER membrane environment and thus might allow a fast substrate/product exchange during the reaction.

According to the sequence analysis and the structures solved, the topology of cLPCAT3 shows an ER luminal-facing gate for the acyl-CoA substrate, an opposing direction against recently determined structures of MBOAT members, e.g., SOAT1, DGAT1, and HAAT.34–37,46,47 The possibility cannot be ruled out that LPCAT3 adopts a membrane topology opposite to that we proposed, since an exoplasmic/ER lumen localization of DGAT1 and SOAT1 was observed. To test if the proteases used in this assay have sufficient proteolytic activities on the cLPCAT3, we conducted an on-cell protease digestion assay using the sequence-specific proteases HRV-3C to treat the cLPCAT3-overexpressing cells to probe the accessibility of the N- and C-terminus of LPCAT3 (Supplementary Fig. 10a). The results showed that, when the proteases were applied to intact cells, the protease recognition sequence at the C-terminal of cLPCAT3 can be cleaved but that at the N-terminal of cLPCAT3 was only slightly cleaved (Supplementary Fig. 10c), indicating a cytoplasm-localized N-terminal without signaling peptide could be found in some LPCAT3s, since an exoplasmic/ER lumen localization of DGAT1, and SOAT1 was observed. To test if the proteases were used in this assay have sufficient proteolytic activities on the cLPCAT3, we conducted an on-cell protease digestion assay using the sequence-specific proteases HRV-3C to treat the cLPCAT3-overexpressing cells to probe the accessibility of the N- and C-terminus of LPCAT3 as suggested in our structural model. To test if the proteases used in this assay have sufficient proteolytic activities on the cLPCAT3 in the membrane-bound state, a control experiment was conducted on the membrane debris prepared by sonication-disruption of the cells overexpressing cLPCAT3, and the results confirm that the protease recognition sequence at both N- and C-terminus of cLPCAT3 can be cleaved by the proteases after cell disruption (Supplementary Fig. 10c). We believe further analysis should be conducted to reliably establish the topology of LPCAT3 since the assay on the overexpressed proteins might introduce unexpected artifact due to the unnatural expression level and localization. However, a further question is raised about the substrate availability if our current hypothesis is true, since the arachidonoyl CoA are mainly synthesized in the cytoplasm by long-chain acyl-CoA synthetase such as ACSL4.8,9,50 The transport of arachidonoyl CoA across the ER membrane is thus required for the lipid remodeling catalyzed by LPCAT3, and the mechanism underlying this process is yet to be elucidated.

In a conclusion, we determined the structures for the critical enzyme in the phospholipid remodeling, LPCAT3, in its apo-, LPC-bound, and arachidonoyl CoA-bound states. In those structures, the binding pockets for both acyl-donor and receptor were mapped and the arrangement of the catalytic residues provide insights into the mechanism of acyl transferring reaction. The T-shape chamber revealed in our structures, in combination with the lateral gate and side pocket, show the structural basis for the substrate preferences of LPCAT3 and substrate/product exchange process.

Methods

Protein expression and purification. The coding cassettes for Gallus gallus LPCAT3 (cLPCAT3, Uniprot ID A01A11RNGS8, https://www.uniprot.org/uniprot/A01A11RNGS8) and Homo sapiens (hLPCAT3, Uniprot ID Q6P1A2, https://www.uniprot.org/uniprot/Q6P1A2) were synthesized and cloned into pFastBac Dual vector and pcDNA3.4 vector modified to introduce a Human Rhinovirus 3C Proteinase cleavage-Stop tag at the C-terminus of cLPCAT3s. Bac-to-Bac Baculovirus Expression System (Invitrogen) was used to express the LPCAT3s protein for crystallization trial. The recombinant baculovirus encoding cLPCAT3 or hLPCAT3 was generated and infected into Spodoptera frugiperda cell line Sf9 for overexpression. The infected cells were further cultured for 60–70 h and collected by centrifugation (1500 × g, 10 min, 4 °C). All the purification procedures were carried out at 4 °C. Firstly, the cell pellets were homogenized in a Low Salt buffer (10 mM NaCl, 10 mM HEPES, pH 7.5) containing 1 mM Tris(2-carboxyethyl)phosphine (TCEP) and 1 mM PMSF (phenylmethyleneosulfonyl fluoride). The cell debris was harvested by centrifugation (45,000 × g, 25 min, 4 °C) and the supernatant was pooled and concentrated to 1 mM TCEP, 1 mM PMSF, 5 mM MgCl2, 0.1 mg mL−1 DNase I. The membrane fraction was collected again by centrifugation. The pellet was resuspended and homogenized in Lysis Buffer (150 mM NaCl, 20 mM HEPES, pH 7.5, 10% (v/v) Glycerol) in the presence of 1 mM TCEP, 5 mM MgCl2, 0.1 mg mL−1 DNase I, 1× protease inhibitor cocktail (MCE). The membrane was solubilized with 1% (v/v) n-Dodecyl–β-D-Maltoside (Excedrin) at 4 °C for 2 h. The solubilization slurry was clarified by centrifugation at 45,000 × g for 45 min, and the LPCAT3s proteins were further purified by affinity chromatography using Strept-Tactin resins (IBA). The resins was washed by Lysis Buffer containing 1 mM TCEP, 2.4 mM n-undecyl-β-D-maltopyranoside (Anatract) and the proteins were eluted by removing the buffer supplemented with 5 mM D-desthiobiotin. The elution peak were then pooled and concentrated to approximately 7 mg mL−1 and then trypsin was added to a concentration of 10 μg mL−1. After incubating for 30 min at 4 °C, the trypsin-treated sample was subjected to size-exclusion chromatography using Superdex 200 Increase 10/300 GL column under a High Salt buffer (1 M NaCl, 35 mM HEPES, pH 7.5) containing 1 mM TCEP, 1 mM PMSF, 5 mM MgCl2, 0.1 mg mL−1 DNase I, 1× protease inhibitor cocktail (MCE). The membrane was solubilized with 1% (v/v) n-Dodecyl–β-D-Maltopyranoside (Excedrin) at 4 °C for 2 h. The solubilization slurry was clarified by centrifugation at 45,000 × g for 45 min at 4 °C, the supernatant was subjected to the affinity chromatography using Strept-Tactin resins and the LPCAT3 proteins eluted by the Lysis Buffer with 1 mM TCEP, 0.1 % GDN (w/v) Anatract, and 5 mM D-desthiobiotin, pH 7.5. The Twin-Strep tags of LPCAT3 proteins were removed with DNase I, 1× protease inhibitor cocktail at 4 °C for 2 h. After centrifugation at 45,000 × g for 45 min at 4 °C, the supernatant was subjected to the affinity chromatography using Strept-Tactin resin. The elution fractions corresponding to the dimeric LPCAT3 protein were further purified by size-exclusion chromatography using Superdex 200 Increase 10/300 GL column in a mobile phase containing 150 mM NaCl, 20 mM HEPES, pH 7.5, 1 mM TCEP and 0.01% (v/v) GDN. To purify the cLPCAT3 in complex with arachidonoyl-CoA and lysophosphatidylcholine (12:0, 1 mg mL−1 arachidonoyl-CoA lithium salt (Arachidonoyl-CoA Sigma) or 0.1 mg mL−1 lysophosphatidylcholine (12:0, Avanti Polar Lipids, Inc.) was added during the membrane solubilization and the affinity chromatography, respectively. The elution fractions corresponding to the dimeric LPCAT3 were pooled and re-subjected to size-exclusion chromatography using Superdex 200 Increase 10/300 GL column with the same mobile phase. The fractions of elution peak were then pooled and concentrated to approximately 7 mg mL−1, with 0.2 mM Arach-CoA-Li or 0.5 mM Lyso-PC (12:0) supplemented, respectively.
Cryostalization and X-ray data collection. Cryocrytalization steps were extensively performed on both hLPCAT3 and cLPCAT3 using both vapor diffusion and liquid cubic face up down protocols. The crystals were soaked up by DMSO vapor diffusion at 16°C and harvested in 14–28 days by directly flash freezing into liquid nitrogen. The crystals with the best diffraction capacity were grown by mixing trypsin-digested cLPCAT3 with a solution containing 50 mM Magnesium acetate (Sigma), 100 mM MES, pH 6.0, 25% (v/v) PEG 400, and 1% (v/v) Formamide. The best crystals were harvested and cryoprotected by soaking for 30 min in a solution containing 32% PEG 400, 100 mM MES, pH 6.0, 50 mM magnesium acetate, and then flash-frozen into liquid nitrogen. The diffraction data were collected at the Shanghai Synchrotron Radiation Facility (beamlines stations BL18U1 and BL19U1) with a wavelength of 0.97883 Å and a temperature of 100 K.

Electron Microscopy: Data preparation and collection. The cryo-grams were prepared using Thermo Fisher Vitrobot Mark IV operated at 8°C with 100% humidity. 3.2 μL of concentrated protein solution with arachidonoyl-CoA (ara-CoA) or lysophosphatidylcholine (LPC) were applied to glow-discharged holey carbon grids (Quantifoil R1.2/1.3, Au, 300 mesh). The protein sample was incubated for 10 s and then blotted with filter paper (Waterman) for 1.5 s. The grids were then plunged into the liquid ethane cooled with liquid nitrogen. The cryo-grids were firstly checked by 200 kV Talos Arctica (FEI) equipped with a Falcon III detector (Thermo Fisher Scientific) and a dataset was collected to confirm the sample quality and generate an initial model. For super resolution data collection, an overall resolution of 3.49 Å were belonged to the best class were subjected into Non-uniform Re projection in Phenix package and Coot The ara-CoA or LPC ligands were found and refined by the program LigandFit and Real-space refinement in Phenix package, respectively. The percentage of Ramachandran outliers is 0.7%, and the percentage value of Ramachandran allowed and favored are 7.7% and 91.5%, respectively.

TLC-based activity assay. The lysophosphatidylcholine acyltransferase (LPCAT) activity of LPCAT3 was determined by monitoring the appearance and the intensity of the fluorescent band generated from the incorporation of the arachidonyl group from ara-CoA into LPC and phosphatidylcholine (LPCG) and Coot The ara-CoA or LPC ligands were found and refined by the program LigandFit and Real-space refinement in Phenix package, respectively. The percentage of Ramachandran outliers is 0.7%, and the percentage value of Ramachandran allowed and favored are 7.7% and 91.5%, respectively.

Crosslinking assay on membrane-bound cLPCAT3. Exp293 cells were transfected with expression vector carrying CDNA for wild-type cLPCAT3 or its mutants and harvested after 60 h. Cells were disrupted by sonication and membrane pellets were collected at 45°C, 15000 g for 10 min. The pellets were resuspended and homogenized in Lysis Buffer (150 mM NaCl, 20 mM HEPES, pH 7.5, 10% (v/v) Glycerol) in the presence of 1 mM TCEP, 5 mM MgCl₂, 0.1 mg mL⁻¹ Dnase I, 1× protease inhibitor cocktail (MCE). (DSS (disuccinimidyl suberate, ThermoFisher Scientific Inc.) was used as crosslinking reagent. The total volume of each reaction was 50 μL and the same volume of DSS (150 mg mL⁻¹) different concentrations was added and the pure DMSO was also added as a negative control. To initiate the crosslinking reaction, DSS dissolved in dimethyl sulfoxide (DMSO) was added into the membrane preparation to various concentrations as indicated in Fig. 6d. The reaction mixture was incubated at room temperature for 30 min and then quenched by adding Tris-HCl (pH 7.5) to a final concentration of 50 mM. The mixture was solubilized with 1% (w/v) Digitonin (Merck KGaA) at 4°C for 2 h. The solubilization slurry was clarified by centrifugation and the supernatants were subjected to SDS-PAGE followed by Western blot analysis. Mouse anti-Strep II-tag multi antibody (AbClonal Inc.) was used as the primary antibody and HRP coupled anti-mouse antibody as the secondary antibody. The blotting images were photographed with Amersham Imager 600 (GE Healthcare).

On-cell protease digestion assay. The coding cassettes of cLPCAT3 was cloned into pcDNA3.4 vector with a N-terminal Flag tag and a C-terminal Twin-Strep tag, respectively. For LPCAT3 with ara-CoA, 4,662,400 particles were firstly extracted with 8x binning and the 2D classifications excluded particles with poor quality. 3,700,472 particles were then re-extracted with 2x binning and subjected to the global 3D classification with a reference from 200 kV EM data processing. 1,640,907 particles were automatically picked using Gautomatch-v0.56 (developed by Kai Zhang) with a 2D reference from 200 kV EM data processing. 1,640,907 particles were then re-extracted with 2× binning and subjected to 3D classifications. After two rounds of 3D classification, 837,336 particles corresponding to suitable classes were re-extracted without binning and subjected to processing with cryoSPARC. 292,613 particles were subjected to Ab-initio Reconstruction and four models were generated and pooled into Heterogeneous Refinement, and after six cycles of classification, 282,382 particles belonged to the best class were subjected into Non-uniform Refinement (Legacy) with C2 symmetry and an adaptive solvent mask, thereby yielding a map with an overall resolution of 3.49 Å. Local resolution estimation was performed by cryoSPARC and all the resolutions were estimated using the gold-standard Fourier shell correlation 0.143 criteria with the high-resolution noise substitution. For LPCAT3 with LPC, 807,037,719 particles were firstly extracted with 8x binning and the 2D classifications excluded particles with poor quality. 5,925,352 particles were re-extracted with 2x binning and subjected to 3D classification. After four cycles of 3D classification, 852,955 particles corresponding to suitable classes were re-extracted without binning and further processed with cryoSPARC. Ab-initio Reconstruction were used to generate four models and the same particles were pooled into Heterogeneous Refinement. After four rounds of iterations, 223,896 particles were selected and Non-uniform Refinement was conducted with C2 symmetry and an adaptive solvent mask, thereby yielding a map with an overall resolution of 3.57 Å. Local resolution estimation was performed by cryoSPARC and all the resolutions were estimated using the gold-standard Fourier shell correlation 0.143 criteria with the high-resolution noise substitution.

Model building and refinement. For the X-ray diffraction data processing on cLPCAT3 crystals, an initial model was built using the Protein Structure Prediction page (https://folding.en.tcd.ie/). The crystallography data was processed using program HKL-2000 (HKL-2000 version 716.1), then solved using molecular replacement in Phaser (packaged in Phenix version 1.19.2- 4158) and was refined with program Coot (Coot version 0.9.5.37), and Buster (BUSTER 2.10.3, Cambridge, United Kingdom: Global Phasing Ltd.).

The building model for cryo EM data was performed with program Coot using the crystal structure of cLPCAT3core as the starting model. The initial model was manually refined and then the real-space refinement with the Real-space refinement package52,53 and Coot The ara-CoA or LPC ligands were found and refined by the program LigandFit and Real-space refinement in Phenix package, respectively. The percentage of Ramachandran outliers is 0.7%, and the percentage value of Ramachandran allowed and favored are 7.7% and 91.5%, respectively.
(1:10,000) by skim milk in TBST in prior to use. Images were captured by Amersham Imager 600.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

The cryo-EM models have been deposited in the EMDB under accession code 7EW7. The cryo-EM maps have been deposited in the Electron Microscopy Data Bank (EMDB) with accession codes EMD-31442 and EMD-31443. All the other data are available from the corresponding authors upon reasonable request. Source data are provided with this paper.

Received: 15 July 2021; Accepted: 8 November 2021; Published online: 25 November 2021

**References**

1. van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. *Nat. Rev. Mol. Cell Biol.* 9, 112–124 (2008).
2. Yamashita, A., Sugita, T. & Waku, K. Acyltransferases and transacylases involved in fatty acid remodeling of phospholipids and metabolism of bioactive lipids in mammalian cells. *J. Biochem.* 122, 1–16 (1997).
3. Schlame, M., Rua, D. & Greenberg, M. L. The biosynthesis and functional role of cardiolipin. *Prog. Lipid Res.* 39, 257–288 (2000).
4. Kennedy, E. P. & Weiss, S. R. The function of cytidine coenzymes in the biosynthesis of phospholipides. *J. Biol. Chem.* 222, 193–214 (1956).
5. Lands, W. E. Metabolism of glycerolipids; a comparison of lecithin and triglyceride synthesis. *J. Biol. Chem.* 231, 883–888 (1958).
6. Lands, W. E. Stories about acyl chains. *Biochim. Biophys. Acta* 1483, 1–14 (2000).
7. Holub, B. J. & Kusis, A. Metabolism of molecular species of diacylglycerolipids. *Adv. Lipid Res.* 45, 105–1063 (2012).
8. MacDonald, J. J. & Sprecher, H. Phospholipid fatty acid remodeling in mammalian cells. *Biochim. Biophys. Acta* 1084, 105–121 (1991).
9. Chen, X., Hyatt, B. A., Mucenski, M. L., Mason, R. J. & Shannon, J. M. Identification and characterization of a phospholipid:diacylglycerol acyltransferase in alveolar type II cells. *Proc. Natl Acad. Sci. USA* 103, 11724–11729 (2006).
10. Nakanishi, H. et al. Cloning and characterization of mouse lung-type acyl-CoA:lyso phospholipid acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. *J. Biol. Chem.* 281, 20140–20147 (2006).
11. Shindou, H. et al. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acyl-CoA:lyso-PAF acyltransferase. *J. Biol. Chem.* 282, 6532–6539 (2007).
12. Zhao, Y. et al. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. *J. Biol. Chem.* 283, 8258–8265 (2008).
13. Hishikawa, D., Hashidate, T., Shimizu, T. & Shindou, H. Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells. *J. Lipid Res.* 55, 799–807 (2014).
14. Guan, C. et al. Structural insights into the inhibition mechanism of human sterol O-acyltransferase 1 by a competitive inhibitor. *Nat. Commun.* 11, 2478 (2020).
15. Qian, H. et al. Structural basis for catalysis and substrate specificity of human ACAT1. *Nature* 581, 333–338 (2020).
16. Xue, H. et al. Structure and catalytic mechanism of a human triacylglycerol-synthesizing enzyme. *Nature* 581, 323–328 (2020).
17. Wang, L. et al. Structure and mechanism of human diacylglycerol O-acyltransferase 1. *Nature* 581, 329–332 (2020).
18. Han, Y. et al. Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism. *Nat. Commun.* 12, 449 (2021).
19. Kall, L., Krogh, A. & Sonnhammer, E. L. Advantages of combined transmembrane topology and signal peptide prediction—the Phobius web server. *Nucleic Acids Res.* 35, W429–W432 (2007).
20. Ho, B. K. & Gruschwitz, F. HOLLOW: generating accurate representations of channel and interior surfaces in molecular structures. *BMC Struct. Biol.* 8, 49 (2008).
21. Punjani, A., Rubinstein, J. I., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* 14, 290–296 (2017).
22. Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. *J. Struct. Biol.* 180, 519–530 (2012).
23. Jain, S. et al. Characterization of human lysophosphatidylcholine acyltransferase 3 J. Lipid Res. 50, 1563–1570 (2009).
24. Martin, S. A., Gijon, M. A., Voelker, D. R. & Murphy, R. C. Measurement of lysophosphatidylcholine acyltransferase activities using substrate competition. *J. Lipid Res.* 55, 782–791 (2014).
25. Marsh, D. & Pali, T. Lipid conformation in crystalline bilayers and in crystals of transmembrane proteins. *Chem. Phys. Lipids* 141, 48–65 (2006).
26. Jiang, Y., Benz, T. L. & Long, S. B. Substrate and product complexes reveal mechanism of Hedgehog acylation by HHAT. *Science* 372, 1215–1219 (2021).
27. Fensholt, F. et al. Photochemical probe identification of a small-molecule inhibitor binding site in hedgehog acyltransferase (HHAT®). *Angew. Chem. Int Ed. Engl.* 50, 13542–13547 (2011).
28. Ma, D. et al. Crystal structure of a membrane-bound O-acyltransferase. *Nature* 562, 286–290 (2018).
29. Grevenoog, T. J., Klett, E. L. & Colemans, R. A. Acyl-CoA metabolism and partitioning. *Annu. Rev. Nutr.* 34, 1–30 (2014).
30. Soupenne, E. & Kuipers, F. A. Mammalian long-chain acyl-CoA synthetases. *Exp. Biol. Med (Maywood)* 233, 507–521 (2008).
31. Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* https://doi.org/10.7554/elife.42166 (2018).
32. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* 14, 331–332 (2017).
Acknowledgements
The authors thank Drs. Ming Zhou, Tingbo Ding, Sheng Wang, and Lijun Wang (for scientific discussion); Yijun Gu, Rijing Liao, and Mi Cao (for assistance with the data analysis). This work is supported by National Key Research and Development Program of China (2018FY1004704 and 2017YFC1001303, Y. Cao), National Natural Science Foundation of China (82072468, Y. Cao), the Shanghai Science and Technology Committee (20S11902000, Y. Cao), SHIPM-pi fund (No. JY201804, Y. Cao) from Shanghai Institute of Precision Medicine, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. This work is also supported by Innovative Research Team of High-level Local Universities in Shanghai (SSMU-ZLCX20180600, M. Lei and Y. Cao) and the Special Project of Shanghai Synchrotron Radiation Facility (SSRF) BL18U1 (2020-NFPS-ZD-000146, L. Zhou).

Author contributions
Y. Cao, L. Zhou, and X.C. Jiang initiated the study. Y. Cao, Q. Zhang, M. Lei, J. Zhao, and A. Qin designed research. Y. Cao, Q. Zhang, and X.C. Jiang wrote the paper. Q. Zhang, Y. Chen, L. Jao, and K. Hu performed the purification and EM sample preparation. Q. Zhang, B. Rao, S. Li, Y. Shen, and Y. Xia collected and analyzed the data. Q. Zhang conducted the biochemical assay. Y. Cao and D. Yao determined the structure. We thank the staff members of the Electron Microscopy System and Mass Spectrometry System at Shanghai Institute of Precision Medicine for providing technical support and assistance in data collection. SSRF beamlines BL18U1 and BL19U1 are used for X-ray crystallography data collection.

Competing interests
The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Yu Cao.

Peer review information

Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information

is available at http://www.nature.com/reprints

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2021